People with Huntington’s disease who develop psychosis tend to have worse cognitive and behavioral disturbances, reduced ability to function, and fewer involuntary movements than patients who do not experience these psychiatric symptoms, a new study reports. The study, titled “Psychosis and longitudinal outcomes in Huntington disease: the…
News
Analysis of handwriting movements using a pen tablet and specialized software can accurately distinguish people with Huntington’s disease who are still asymptomatic from those without the disease, a new study suggests. The findings also reveal that certain stroke features differ significantly between healthy individuals and patients who are already…
Mutations associated with Huntington’s disease increase nerve cells’ resistance to high levels of manganese, according to a recent study. The results of the study, “Huntington’s disease associated resistance to Mn neurotoxicity is neurodevelopmental stage and neuronal lineage dependent,” were published in NeuroToxicology. Manganese (Mn) is…
A combined data analysis of five studies examining the effects of short-term exercise interventions in Huntington’s disease (HD) did not find any evidence of statistically significant motor improvements. The investigators suggest more supervised trials of longer duration and with common outcomes are necessary in order to evaluate the…
Levels of certain trace metals are altered in the blood of people with Huntington’s disease, a new study found, suggesting that measuring and/or targeting these metals may be useful for studying, or perhaps treating, Huntington’s. The results, “Trace elements profile in the blood of Huntington’ disease patients,”…
Increasing the levels of a natural enzyme called nicotinamide mononucleotide adenylyltransferase — or Nmnat — halts the formation of mutant huntingtin (Htt) protein aggregates that build up in nerves cells in Huntington’s disease, a fruit fly study shows. “We discovered the neuroprotective role of a cellular ‘housekeeping’…
Different types of apathy — a common psychiatric symptom of Huntington’s disease — are associated with specific alterations in the brain’s white matter in patients at different stages of the disease, a study finds. White matter refers to regions of the brain made up of myelinated…
Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told Bionews Services, publisher…
Laquinimod, an experimental immunomodulatory therapy developed by Active Biotech and Teva Pharmaceuticals, reduced signs of inflammation and brain atrophy (shrinkage) in patients with Huntington’s disease, data from an exploratory analysis of a Phase 2 trial show. The new data were presented by Active Biotech in three posters…
Huntington’s disease may manifest itself for the first time during neurulation, a process in which the neural tube — the precursor of our nervous system (brain and spinal cord) — develops while an embryo is forming, scientists report. These findings are in the study “Self-organizing neuruloids…
Recent Posts
- It’s OK to reach out for help during the February slump
- Huntington’s treatment safely slows disease over 9 months in early trial
- A new puppy gives my gene-positive wife a sense of purpose
- Toward a better understanding of anger as a symptom of Huntington’s disease
- Actor Will Forte shares family story in Teva awareness campaign
- Finding ‘space in the middle’ to deal with life’s challenges
- What a compassionate reset looks like in life with Huntington’s
- Ingrezza engages with therapeutic target more strongly than Austedo
- Anticipation of a possible new clinical trial has us holding on to hope
- What caregiver burnout is really about — and what you can do about it